2. Summary of included studies and baseline psychopathology.
| Study | Intervention | Dosage | Length | As adjunct (Y/N) | Assessment tool | BPRS/PANSS | HAMD/CDSS |
SANS/ PANSS negative |
SANS/ PANSS negative |
||
| Intervention | Control | Intervention | Control | Intervention | Control | ||||||
| Belanoff 2001 | Mifepristone | 600 mg/d | 4 days | N | BPRS, HAMD | 51.5 (3.5) | 45.3 (11.6) | 37.5 (12.0) | 29.0 (5.3) | ‐ | ‐ |
| DeBattista 2006 | Mifepristone | 600 mg/d | 7 days | N | BPRS, HAMD | 55.8 (11.6) | 55.7 (9.2) | 37.3 (8.4) | 37.3 (7.5) | ‐ | ‐ |
| Flores 2006 | Mifepristone | 600 mg/d | 8 days | Y | BPRS, HAMD | 46.9 (5.7) | 50.1 (8.5) | 29.3 (5.0) | 31.5 (5.1) | ‐ | ‐ |
| Gallagher 2005 | Mifepristone | 600 mg/d | 7 days | Y | BPRS, HAMD | 31.5 (10.1) | 27.8 (9.7) | 9.6 (8.8) | 11.7 (8.1) | ‐ | ‐ |
| Nachshoni 2005 | DHEA | 100 mg/d | 7 days | Y | BPRS | 23.8 (12.2) | 24.9 (9.6) | ‐ | ‐ | ‐ | ‐ |
| Ritsner 2006 | DHEA | 200 mg/d | 6 weeks | Y | PANSS | 91.6 (17.1) | 95.6 (17.2) | ‐ | ‐ | 25.3 (6.3) | 26.7 (6.2) |
| Strous 2003 | DHEA | Titrated up to 100 mg/d | 6 weeks | Y | PANSS, HAMD, SANS | 66.4 (20.9) | 63.8 (18.8) | 8.9 (5.3) | 7.0 (5.6) | 47.9 (13.7) | 40.8 (16.5) |
| Strous 2007 | DHEA | Titrated up to 150 mg/d | 8 weeks | Y | PANSS, CDSS, SANS | 65.5 (15.6) | 65.1 (18.8) | 3.0 (3.7) | 4.3 (3.2) | 52.8 (15.9) | 39.7 (23.9) |
| Ritsner 2010 | DHEA | DHEA 400 mg/d | 8 weeks | Y | PANSS | 46.2 (11.1) | 37.1 (8.8) | ‐ | ‐ | 25.8 (6.1) | 22.8 (5.8) |
| Marco 2002 | Ketoconazole | Titrated up to 800 mg/d | 4 weeks | Y | PANSS, HAMD | 37.5 (6.7) | 32.4 (6.3) | 20.0 (6.0) | 20.0 (5.1) | 21.6 (5.4) | 17.4 (5.1) |
| Newcomer 1998 | Dexamethasone | Successive doses of 0.5, 1, 1 and 1 mg | 4 days | Y | BPRS, SANS | No data reported | No data reported | ‐ | ‐ | No data reported | No data reported |